SCHEMBL12324751

SCHEMBL12324751

Oc1ccc2nc3cc(Br)ccn3c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPM1 P06748 3/20 0.43
ALK Q9UM73 3/20 0.43
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GLA P06280 2/20 0.40
POLB P06746 2/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
TLR9 Q9NR96 1/20 0.37
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
RAD51 Q06609 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18838772 0.81 IKBKB (0.47) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL21623397 0.78 ALK (0.48) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL12324172 0.77 ALK (0.59) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL31031257 0.76 ALDH1A1 (0.41) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL31031234 0.73 NPM1 (0.36) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL2162685 0.72 NPM1 (0.44) NPM1ALKMAPTRAD51
SCHEMBL2163001 0.71 MAPT (0.36) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL30952765 0.70 KDM4E (0.66) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL21616811 0.70 KDM4E (0.66) NPM1ALKKDM4EALDH1A1GLA
SCHEMBL22309752 0.68 NPM1 (0.37) NPM1ALKALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 NPM1 1761/4885ALK 4738/4885KDM4E 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.